The use of the drug everolimus to reduce hypertrophy of the heart?s left ventricle in kidney transplant recipients

The effect of the mammalian Target Of Rapamycin (mTOR) inhibitor everolimus on reducing left ventricular hypertrophy in renal transplant recipients (RTRs)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN93681079

Enrollment

Registered

2011-04-08

Start date

2008-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non diabetic patients receiving kidney transplants Surgery

Interventions

1. Randomisation to either everolimus (EVL) plus reduced-exposure cyclosporine A (CsA) or standard-dose CsA 2. Anti-interleukin-2 receptor monoclonal antibodies for induction and steroids in both grou

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non diabetic renal transplant recipients (RTRs)

Exclusion criteria

Exclusion criteria: 1. Patients receiving second transplant 2. Patients receiving dual transplant 3. Diabetic patients 4. Patients with severe cardiac valvular abnormalities

Design outcomes

Primary

Measure	Time frame
Change in left ventricular mass index which is assessed by echocardiography after 1 year	—

Secondary

Measure	Time frame
1. Changes in renal graft function at one and three years 2. Incidence of acute rejection episodes at one and three years	—

Countries

Italy

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026